Exploratory study of AVI-4065 injection to design therapeutic dosing for chronic active HCV patients

Trial Profile

Exploratory study of AVI-4065 injection to design therapeutic dosing for chronic active HCV patients

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2012

At a glance

  • Drugs AVI 4065 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 14 Apr 2008 Status changed from recruiting to discontinued. According to ClinicalTrials.gov, the study was terminated because of limited viral load reduction in patients with hepatitis C.
    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top